Stockscreener 앱 받기
1.33
3.91%
0.05
시간 외 거래:
1.31
-0.02
-1.50%
Pliant Therapeutics Inc 주식(PLRX)의 최신 뉴스
Pliant Therapeutics to present PLN-101095 cancer trial data at AACR By Investing.com - Investing.com South Africa
Pliant Therapeutics to present PLN-101095 cancer trial data at AACR - Investing.com Australia
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Investing News Network
AACR 2026 to feature Pliant Therapeutics Phase 1 PLN-101095 results at major symposium - Traders Union
Pliant Therapeutics Announces Upcoming Presentation Of Phase 1 Clinical Trial Of PLN-101095 In Patients With Solid Tumors At The 2026 Aacr Annual Meeting - TradingView
Experimental pill for immunotherapy-resistant tumors set for 2026 AACR data debut - Stock Titan
Clinical Progress and Disclosure Timeline: Biopharmaceutical company Pliant Therapeutics (NASDAQ: PLRX) announced that Phase I clinical trial data for its solid tumor candidate drug Pln-101095 will be officially released at the 2026 American Association f - Bitget
Portfolio Shifts: Is Pliant Therapeutics Inc benefiting from interest rate changes2026 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
Prosight Management Cuts Stake in Pliant Therapeutics - National Today
Prosight Management LP Has $30,000 Position in Pliant Therapeutics, Inc. $PLRX - MarketBeat
How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance - The Globe and Mail
Oppenheimer Remains a Hold on Pliant Therapeutics (PLRX) - The Globe and Mail
Canaccord Genuity Group Issues Pessimistic Forecast for Pliant Therapeutics (NASDAQ:PLRX) Stock Price - MarketBeat
Pliant Therapeutics (PLRX): Canaccord Genuity Adjusts Price Targ - GuruFocus
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (PLRX) and Cytokinetics (CYTK) - The Globe and Mail
Pliant Therapeutics (PLRX) Analyst Rating Update: Piper Sandler Lowers Price Target | PLRX Stock News - GuruFocus
Piper Sandler cuts Pliant Therapeutics stock price target to $3 By Investing.com - Investing.com Canada
Pliant Therapeutics Reports Q4 2025 Financial Results and Corporate Update – 8-K Filing Summary - Minichart
Pliant Therapeutics 2025 Annual Report: Business Overview, Risks, Regulatory Environment, and Competitive Landscape - Minichart
Pliant Therapeutics (PLRX) Advances Oncology Drug Development - GuruFocus
Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
PLRX: Net loss improved to $149.3M as focus shifted to PLN-101095; $192.4M cash on hand - TradingView
Pliant Therapeutics 10‑K — No Revenue; Net Loss $2.43 EPS on $149.3M Net Loss - TradingView
PLRX: PLN-101095 advances to Phase 1b after strong Phase 1 data; net loss narrows on lower expenses - TradingView
Oncology data and cost cuts reshape Pliant Therapeutics (NASDAQ: PLRX) - Stock Titan
BRIEF-Pliant Therapeutics Q4 Net Income USD -23.577 Million - TradingView
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - ChartMill
Market Rankings: Is Pliant Therapeutics Inc stock good for income investorsQuarterly Profit Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Lyell Immunopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration - The Globe and Mail
PLRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pliant Therapeutics (PLRX) extends stockholder rights plan expiration to 2027 - Stock Titan
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference - Yahoo Finance
PLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Pliant Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Momentum Shift: Is M I Homes Inc currently under institutional pressure2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PLRX: Lead oncology program shows strong early efficacy and safety, with phase Ib starting in Q2 - TradingView
Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT) - The Globe and Mail
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration - Seeking Alpha
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - The Manila Times
Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Pliant CEO and CFO join Oppenheimer virtual fireside chat Feb. 25 - Stock Titan
Investment Recap: What is the Moat Score of Pliant Therapeutics IncJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
PLRX Should I Buy - Intellectia AI
Should I hold or sell Pliant Therapeutics Inc. stock in 20252025 Winners & Losers & Short-Term Swing Trade Alerts - mfd.ru
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Woodline Partners (PLRX) discloses 3.3% beneficial stake in Pliant - Stock Titan
PLRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Chart Watch: What is Pliant Therapeutics Inc.’s book value per shareEarnings Growth Report & Weekly High Potential Stock Alerts - mfd.ru
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Up 21.0% in January - MarketBeat
Idiopathic Pulmonary Fibrosis Market: Expanding Revenue - openPR.com
Aug Analyst Calls: Is GENC on track to beat earningsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Portfolio Shifts: Is Pliant Therapeutics Inc. a potential multi baggerJuly 2025 Levels & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Weekly Earnings: How cyclical is Pliant Therapeutics Incs revenue streamExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
Breakout Zone: Why is Pliant Therapeutics Inc stock going upJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of “Reduce” from Analysts - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Reduce" from Analysts - MarketBeat
Citadel Advisors LLC Acquires Additional Shares in Pliant Therapeutics Inc - GuruFocus
Quarterly Earnings: Is Pliant Therapeutics Inc a stock for growth or value investorsJuly 2025 Levels & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
1.20%
0.06%
자본화:
|
볼륨(24시간):